Vitamin D Binding Protein-Macrophage Activating Factor Inhibits HCC in SCID Mice (Q39653734)

13 September 2017

title

Vitamin D binding protein-macrophage activating factor inhibits HCC in SCID mice (English)

1 reference

13 September 2017

Vitamin D Binding Protein-Macrophage Activating Factor Inhibits HCC in SCID Mice (English)

1 reference

https://api.crossref.org/works/10.1016/J.JSS.2010.07.057

16 July 2024

0 references

1 reference

hepatocellular carcinoma

1 reference

Koichi Nonaka

1

1 reference

13 September 2017

Shinya Onizuka

2

1 reference

13 September 2017

Hiromi Ishibashi

3

1 reference

13 September 2017

Yoshihiro Uto

4

1 reference

13 September 2017

Hitoshi Hori

5

1 reference

13 September 2017

Toshiyuki Nakayama

6

1 reference

13 September 2017

Nariaki Matsuura

7

1 reference

13 September 2017

Takashi Kanematsu

8

1 reference

13 September 2017

Hikaru Fujioka

9

1 reference

13 September 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20855083

16 July 2024

publication date

17 September 2010

1 reference

full work available at URL

13 September 2017

https://api.elsevier.com/content/article/PII:S0022480410006736?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.JSS.2010.07.057

https://api.elsevier.com/content/article/PII:S0022480410006736?httpAccept=text/plain

16 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.JSS.2010.07.057

Journal of Surgical Research

16 July 2024

published in

1 reference

13 September 2017

volume

172

1 reference

13 September 2017

issue

1

1 reference

13 September 2017

page(s)

116-122

1 reference

The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology

13 September 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.JSS.2010.07.057

Long-term outcome of resection of large hepatocellular carcinoma

16 July 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.JSS.2010.07.057

Role of transplantation in the management of hepatic malignancy.

16 July 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.JSS.2010.07.057

Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators

16 July 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.JSS.2010.07.057

Current management strategy of hepatocellular carcinoma

16 July 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.JSS.2010.07.057

Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models

16 July 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.JSS.2010.07.057

Tumor angiogenesis: therapeutic implications

16 July 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.JSS.2010.07.057

Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice

16 July 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.JSS.2010.07.057

Immunotherapy of BALB/c mice bearing Ehrlich ascites tumor with vitamin D-binding protein-derived macrophage activating factor

16 July 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.JSS.2010.07.057

Gc protein (vitamin D-binding protein): Gc genotyping and GcMAF precursor activity

16 July 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.JSS.2010.07.057

Purification of human serum vitamin D-binding protein by 25-hydroxyvitamin D3-Sepharose chromatography.

16 July 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.JSS.2010.07.057

Vitamin D3 binding protein (group-specific component) is a precursor for the macrophage-activating signal factor from lysophosphatidylcholine-treated lymphocytes

16 July 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.JSS.2010.07.057

Tumor plasticity allows vasculogenic mimicry, a novel form of angiogenic switch. A rose by any other name?

16 July 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.JSS.2010.07.057

Expression of parathyroid hormone/parathyroid hormone-related protein receptor in vascular endothelial cells

16 July 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.JSS.2010.07.057

In vitro and in vivo induction of antiangiogenic activity by plasminogen activators and captopril

16 July 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.JSS.2010.07.057

Pancreatic carcinogenesis: apoptosis and angiogenesis

16 July 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.JSS.2010.07.057

Intratumor microvessel density as a prognostic factor in cancer

16 July 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.JSS.2010.07.057

Molecular cloning of F4/80, a murine macrophage-restricted cell surface glycoprotein with homology to the G-protein-linked transmembrane 7 hormone receptor family

16 July 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.JSS.2010.07.057

Effects of vitamin D(3)-binding protein-derived macrophage activating factor (GcMAF) on angiogenesis

16 July 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.JSS.2010.07.057

Inhibition of angiogenesis by vitamin D-binding protein: characterization of anti-endothelial activity of DBP-maf.

16 July 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.JSS.2010.07.057

Expression of vascular endothelial growth factor in human hepatocellular carcinoma

16 July 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.JSS.2010.07.057

Microvessel density and clinicopathological characteristics in hepatitis C virus and hepatitis B virus related hepatocellular carcinoma

16 July 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.JSS.2010.07.057

Evaluating antiangiogenesis agents in the clinic: the Eastern Cooperative Oncology Group Portfolio of Clinical Trials

16 July 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.JSS.2010.07.057

Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma

16 July 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.JSS.2010.07.057

Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.

16 July 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.JSS.2010.07.057

Optimal amount of monocyte chemoattractant protein-1 enhances antitumor effects of suicide gene therapy against hepatocellular carcinoma by M1 macrophage activation

16 July 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.JSS.2010.07.057

Tumor-infiltrating macrophages can predict favorable prognosis in hepatocellular carcinoma after resection.

16 July 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.JSS.2010.07.057

Macrophage activation increases the invasive properties of hepatoma cells by destabilization of the adherens junction.

16 July 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.JSS.2010.07.057

Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes

16 July 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.JSS.2010.07.057

Gc protein-derived macrophage activating factor (GcMAF): isoelectric focusing pattern and tumoricidal activity

16 July 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.JSS.2010.07.057

Angiostatin induces and sustains dormancy of human primary tumors in mice

16 July 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.JSS.2010.07.057

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance

16 July 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.JSS.2010.07.057

16 July 2024

Identifiers

1 reference

13 September 2017

1 reference